A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Weekly Low-dose Methotrexate (LDM) in the Prevention of Cardiovascular Events Among Stable Coronary Artery Disease Patients With Type 2 Diabetes or Metabolic Syndrome
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Methotrexate (Primary) ; Folic acid
- Indications Cardiovascular disorders; Myocardial infarction
- Focus Therapeutic Use
- Acronyms CIRT
Most Recent Events
- 24 Jul 2020 Biomarkers information updated
- 08 Aug 2013 New source identified and integrated (Oregon Health and Science University Institutional Review Board; IRB00009594).
- 01 Apr 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.